尽管如今乳腺癌治疗已取得显着进展，但转移性乳腺癌，尤其是三阴性乳腺癌 (TNBC) 仍面临低生存率的挑战。癌症免疫疗法是治疗 HER2 阳性和 TNBC 的一种有前景的方法，但仍然面临耐药性障碍。最近，许多研究将目光投向乳腺癌免疫疗法的耐药性。我们的研究通过细致的文献计量分析，全面了解了这一关键领域的当前研究格局、热点和新兴突破。截至2024年3月26日，Web of Science核心合集中共收集了1341篇有关乳腺癌免疫学耐药的文章，其中包括765篇文章和576篇评论。利用Bibliometrix、CiteSpace和VOSviewer软件检查每年的出版物和引用情况、多产国家、贡献机构、高水平期刊和学者，以及高被引文章、参考文献和关键词。过去七年来，乳腺癌免疫治疗耐药性的研究出现了显着的激增。美国和中国做出了重大贡献，其中哈佛医学院是最多产的机构，并积极开展合作。贡献最大的作者是来自意大利欧洲肿瘤研究所的 Curigliano, G，而来自美国达纳法伯癌症研究所的 Wucherpfennig, K. W. 的被引用率最高。高产期刊主要关注临床、免疫学和肿瘤学研究。常见的关键词包括“耐药”、“表达”、“肿瘤微环境”、“癌症”、“T细胞”、“治疗”、“化疗”和“细胞”。目前的研究致力于通过生物信息学、基础实验和临床试验的结合来揭示乳腺癌的免疫抵抗机制。人们正在努力制定提高免疫疗法有效性的策略，包括探索联合疗法和药物输送系统的进步。此外，人们还非常关注识别可以预测患者对免疫学反应的新型生物标志物。这项研究将为研究人员提供乳腺癌免疫学耐药性现有知识的最新概述，为知情决策和解决免疫治疗耐药性创新方法的进一步研究提供宝贵资源。版权所有 © 2024张、蒋、庄、曾、李。

While breast cancer treatments have advanced significantly nowadays, yet metastatic, especially triple-negative breast cancer (TNBC), remains challenging with low survival. Cancer immunotherapy, a promising approach for HER2-positive and TNBC, still faces resistance hurdles. Recently, numerous studies have set their sights on the resistance of immunotherapy for breast cancer. Our study provides a thorough comprehension of the current research landscape, hotspots, and emerging breakthroughs in this critical area through a meticulous bibliometric analysis. As of March 26, 2024, a total of 1341 articles on immunology resistance in breast cancer have been gathered from Web of Science Core Collection, including 765 articles and 576 reviews. Bibliometrix, CiteSpace and VOSviewer software were utilized to examine publications and citations per year, prolific countries, contributive institutions, high-level journals and scholars, as well as highly cited articles, references and keywords. The research of immunotherapy resistance in breast cancer has witnessed a remarkable surge over the past seven years. The United States and China have made significant contributions, with Harvard Medical School being the most prolific institution and actively engaging in collaborations. The most contributive author is Curigliano, G from the European Institute of Oncology in Italy, while Wucherpfennig, K. W. from the Dana-Farber Cancer Institute in the USA, had the highest citations. Journals highly productive primarily focus on clinical, immunology and oncology research. Common keywords include "resistance", "expression", "tumor microenvironment", "cancer", "T cell", "therapy", "chemotherapy" and "cell". Current research endeavors to unravel the mechanisms of immune resistance in breast cancer through the integration of bioinformatics, basic experiments, and clinical trials. Efforts are underway to develop strategies that improve the effectiveness of immunotherapy, including the exploration of combination therapies and advancements in drug delivery systems. Additionally, there is a strong focus on identifying novel biomarkers that can predict patient response to immunology. This study will provide researchers with an up-to-date overview of the present knowledge in drug resistance of immunology for breast cancer, serving as a valuable resource for informed decision-making and further research on innovative approaches to address immunotherapy resistance.Copyright © 2024 Zhang, Jiang, Zhuang, Zeng and Li.